Hematology

• M&A / Deals

Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug

pharminent June 2, 2026

• Clinical Data

ASCO 2026: Kelonia presents positive in vivo CAR-T data in multiple myeloma

pharminent June 2, 2026

• Regulatory

AbbVie snags FDA’s first ADC approval for ultra-rare blood cancer

pharminent May 28, 2026

• Regulatory

FDA hands BeOne, Taiho approvals for blood cancers

pharminent May 14, 2026

• Regulatory

Pfizer receives EC approval for Hympavzi to treat haemophilia

pharminent May 14, 2026

• M&A / Deals

CellCentric raises $220M for a ‘transformative’ multiple myeloma medicine

pharminent May 6, 2026

• M&A / Deals

MSD concludes Terns acquisition to expand CML pipeline

pharminent May 6, 2026

• M&A / Deals

MSD concludes Terns acquisition to expand CML pipeline

pharminent May 6, 2026

• Pipeline

Merck still sees ‘compelling’ outlook for Terns leukemia drug

pharminent April 30, 2026

• M&A / Deals

Eli Lilly acquires Ajax Therapeutics for first-in-class JAK2 inhibitor in myelofibrosis

pharminent April 27, 2026

• Regulatory

Novo Nordisk preps filings for sickle cell drug etavopivat

pharminent April 21, 2026

• Clinical Data

Novo’s late-stage sickle cell win piles pressure on competitors

pharminent April 20, 2026

• M&A / Deals

Merck Chopped $1B Off Terns’ Offer After Seeing Updated Leukemia Data

pharminent April 8, 2026

• Regulatory

Agios mulls early FDA filing for sickle cell therapy

pharminent April 1, 2026

• M&A / Deals

Merck to buy Terns in $6.7B bet on a ‘differentiated’ leukemia drug

pharminent March 25, 2026

• Clinical Data

Karyopharm myeloma drug yields mixed data in myelofibrosis trial

pharminent March 24, 2026